Predicting the magnitude of short-term CD4 + T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy

Abstract

Background

The extent of short-term CD4⁺ T-cell recovery in patients tolerating first-line highly active antiretroviral therapy (HAART) and attaining undetectable HIV RNA levels is inadequately defined.

Methods

We retrospectively analysed patients in four Italian cohorts who started HAART between January 1996 and September 2006. All patients had known HCV coinfection status, did not modify the regimen for 6 months and had <50 HIV RNA copies/ml at the end of the sixth month.

Results

The analysis involved 1,488 patients (1,096 males, 73.7%) with a median age of 43 years (interquartile range [IQR] 39–49); 435 (29.2%) were positive for HCV, 71 (4.8%) were positive for hepatitis B surface antigen (HBsAg) and 76 (5.1%) had experienced a previous AIDS-defining event. At baseline, patient CD4⁺ T-cell counts were 226 cells/μl (IQR 99–332), CD4⁺ T-cell percentages were 14.7% (IQR 8.7–21.2) and HIV RNA levels were 4.91 log₁₀ copies/ml (IQR 4.38–5.34). Overall, 24-week CD4⁺ T-cell recovery was 144 cells/μl (IQR 70–240). At multivariable analysis, T-cell recovery was positively related to the use of a boosted protease inhibitor (P<0.0001) or thymidine analogues (P<0.0001), baseline HIV RNA levels (P<0.0001), the baseline percentage of CD4⁺ T-cells (P<0.0001) and the absence of HCV coinfection (P=0.006). Age, gender, baseline CD4⁺/CD8⁺ T-cell ratio and a history of AIDS-defining events had no independent effect on CD4⁺ T-cell recovery.

Conclusions

Among HIV-infected patients tolerating first-line HAART and with undetectable HIV RNA after 6 months, CD4⁺ T-cell recovery is significantly greater in those without HCV coinfection, with a high baseline viral load, a high baseline percentage of CD4⁺ T-cells and in those treated with a boosted protease inhibitor.

References

Baker

J.V.

, Peng

, Rapkin

CD4⁺ count and risk of non-AIDS diseases following initial treatment for HIV infection.

AIDS 2008; 22: 841–848.

Chêne

, Sterne

J.A.

, May

Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies.

Lancet 2003; 362: 679–686.

Bucy

R.P.

, Hockett

R.D.

, Derdeyn

C.A.

Initial increase in blood CD4⁺ lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues.

J Clin Invest 1999; 103: 1391–1398.

Viard

J.P.

, Burgard

, Hubert

J.B.

Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level.

AIDS 2004; 18: 45–49.

Bosch

R.J.

, Wang

, Vaida

, Lederman

M.M.

, Albrecht

M.A.

Changes in the slope of the CD4 cell count increase after initiation of potent antiretroviral treatment.

J Acquir Immune Defic Syndr 2006; 43: 433–435.

Hunt

P.W.

, Deeks

S.G.

, Rodriguez

Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.

AIDS 2003; 17: 1907–1915.

Smith

C.J.

, Sabin

C.A.

, Lampe

F.C.

The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy.

AIDS 2003; 17: 963–969.

Mocroft

, Phillips

A.N.

, Gatell

Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study.

Lancet 2007; 370: 407–413.

Kaufmann

G.R.

, Bloch

, Finlayson

, Zaunders

, Smith

, Cooper

D.A.

The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy.

AIDS 2002; 16: 359–367.

10.

Keruly

, Moore

Increases in CD4 cell count to 5 years in persons with sustained virologic suppression. 13th Conference on Retroviruses and Opportunistic Infections. 5–8 February 2006, Denver, CO, USA. Abstract 529.

11.

Moore

R.D.

, Keruly

J.C.

CD4⁺ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.

Clin Infect Dis 2007; 44: 441–446.

12.

Antonucci

, Girardi

, Cozzi-Lepri

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Clin Infect Dis 2005; 40: e101–e109.

13.

Phillips

A.N.

, Gazzard

, Gilson

Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count.

AIDS 2007; 21: 1717–1721.

14.

Florence

, Lundgren

, Dreezen

Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study.

HIV Med 2003; 4: 255–262.

15.

Bennett

K.K.

, DeGruttola

V.G.

, Marschner

I.C.

, Havlir

D.V.

, Richman

D.D.

Baseline predictors of CD4 T-lymphocyte recovery with combination antiretroviral therapy.

J Acquir Immune Defic Syndr 2002; 31: 20–26.

16.

Kaufmann

G.R.

, Perrin

, Pantaleo

CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.

Arch Intern Med 2003; 163: 2187–2195.

17.

Gras

, Kesselring

A.M.

, Griffin

J.T.

CD4 cell counts of 800 cells/mm³ or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm³ or greater.

J Acquir Immune Defic Syndr 2007; 45: 183–192.

18.

Lepri

A.C.

, Phillips

A.N.

, d'Arminio Monforte

When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study.

AIDS 2001; 15: 983–990.

19.

Hulgan

, Raffanti

, Kheshti

CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm³.

J Infect Dis 2005; 192: 950–957.

20.

Burcham

, Marmor

, Dubin

CD4% is the best predictor of development of AIDS in a cohort of HIV-infected homosexual men.

AIDS 1991; 5: 365–372.

21.

Moore

D.M.

, Hogg

R.S.

, Yip

, Craib

, Wood

, Montaner

J.S.

CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/ microL.

HIV Med 2006; 7: 383–388.

22.

Gandhi

R.T.

, Spritzler

, Chan

Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384.

J Acquir Immune Defic Syndr 2006; 42: 426–434.

23.

Bosch

R.J.

, Bennett

, Collier

A.C.

, Zackin

, Benson

C.A.

Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy.

J Acquir Immune Defic Syndr 2007; 44: 268–277.

24.

Pakker

N.G.

, Notermans

D.W.

, de Boer

R.J.

Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation.

Nat Med 1998; 4: 208–214.

25.

Zhang

Z.Q.

, Notermans

D.W.

, Sedgewick

Kinetics of CD4⁺ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection.

Proc Natl Acad Sci U S A 1998; 95: 1154–1159.

26.

Mohri

, Perelson

A.S.

, Tung

Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy.

J Exp Med 2001; 194: 1277–1287.

27.

Greub

, Ledergerber

, Battegay

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.

Lancet 2000; 356: 1800–1805.

28.

Braitstein

, Zala

, Yip

Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program.

J Infect Dis 2006; 193: 259–268.

29.

Puoti

, Bonacini

, Spinetti

Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus.

J Infect Dis 2001; 183: 134–137.

30.

The Data Collection on Adverse Events of Anti-HIV Drugs Study Group.

Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.

Arch Intern Med 2006; 166: 1632–1641.

31.

Rockstroh

J.K.

, Mocroft

, Soriano

Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.

J Infect Dis 2005; 192: 992–1002.

32.

Riddler

, Haubrich

, DiRienzo

A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection - ACTG 5142. XVI International AIDS Conference. 13–18 August 2006, Toronto, ON, Canada. Abstract ThLB0204.

33.

Mocroft

, Phillips

A.N.

, Ledergerber

Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.

AIDS 2006; 20: 1141–1150.

34.

Phenix

B.N.

, Angel

J.B.

, Mandy

Decreased HIV-associated T cell apoptosis by HIV protease inhibitors.

AIDS Res Hum Retroviruses 2000; 16: 559–567.

35.

Vlahakis

S.R.

, Bren

G.D.

, Algeciras-Schimnich

, Trushin

S.A.

, Schnepple

D.J.

, Badley

A.D.

Flying in the face of resistance: antiviral-independent benefit of HIV protease inhibitors on T-cell survival.

Clin Pharmacol Ther 2007; 82: 294–299.

36.

Walmsley

, Bernstein

, King

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

N Engl J Med 2002; 346: 2039–2046.

37.

Khanna

, Opravil

, Furrer

CD4⁺ T cell count recovery in HIV type 1–infected patients Is independent of class of antiretroviral therapy.

Clin Infect Dis 2008; 47: 1093–1101.

38.

DeJesus

, Herrera

, Teofilo

Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.

Clin Infect Dis 2004; 39: 1038–1046.

39.

Gallant

J.E.

, DeJesus

, Arribas

J.R.

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

N Engl J Med 2006; 354: 251–260.

40.

Lin

H.M.

, Hughes

Adjusting for regression toward the mean when variables are normally distributed.

Stat Methods Med Res 1997; 6: 129–146.